Comparing GLP-1 Agonists: Dulaglutide vs. Liraglutide
All currently available GLP-1 agonists (albiglutide, dulaglutide, exenatide, liraglutide) have four attributes in common: glucose-dependent stimulation of insulin secretion, glucose-dependent blunting of glucagon secretion, improved satiety, and delay in gastric emptying. These physiologic effects are associated with improved glucose control, less risk for hypoglycemia, and weight loss. Head-to-head trials can inform us about potential differences among the agents, but within this class there is much more in similarity than difference.
To date, head-to-head comparisons of GLP1 agonists have suggested a modest A1c reduction advantage for liraglutide (Victoza). The most recently FDA-approved GLP1 agonist, dulaglutide (Trulicity), is the subject of this head-to-head trial vs. liraglutide. In the AWARD-6 trial, patients (n = 599) were randomized (open-label) to maximum as per-labeling dose of once-weekly dulaglutide 1.5 mg or once-daily liraglutide 1.8 mg.
The degree of A1c reduction at 26 weeks with dulaglutide (1.42%) was slightly greater than liraglutide (1.36%), which did meet the threshold for non-inferiority (the primary outcome of the study). The adverse-effect profiles were very similar, except for a substantially lesser degree of hypoglycemia (0.34 vs. 0.52 events/year) with dulaglutide.
Maximum dose once-weekly dulaglutide is non-inferior to maximum dose once-daily liraglutide.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.